Educational Tools For The Improvement Of Early Advance Care Planning In Adolescents And Young Adults With Advanced Solid Tumors And High-Grade Brain Tumors

Overview

About this study

This clinical trial studies whether educational tools work to improve early advance care planning (ACP) in adolescents and young adults (AYAs) with solid tumors that may have spread from where they first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and high-grade brain tumors. The incidence of AYA cancers is on the rise with approximately 90,000 new diagnoses yearly in the United States. Cancer remains the leading cause of disease-related death among AYAs, which could be due to patients having more advanced disease at presentation. It is recommended that AYAs begin ACP conversations at the start of treatment. ACP includes clarifying goals of care, discussions about end-of-life preferences, and completing a legal document that states the treatment or care a person wishes to receive or not receive if they become unable to make medical decisions (advance directive). The educational tools in this study include an early ACP educational video featuring AYAs with cancer and an ACP appointment geared for AYAs. Patients can access and watch the educational video at home prior to their scheduled ACP appointment. During the ACP appointment, a tailored ACP guide made specifically for AYAs is reviewed and questions regarding ACP are answered. This may help to introduce the importance of key ACP concepts, which may improve early ACP in AYAs with advanced solid tumors and high-grade brain tumors.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

* Age 18-39 at initial cancer diagnosis
* Recently diagnosed (defined as 12 months or less from initial diagnosis or advance stage relapse) with either a stage III/IV solid malignancy or high-grade brain tumor. This includes patients who have stage III/IV recurrence of previously stage I/II solid malignancy
* Actively receiving primary oncologic care at Mayo Clinic Arizona
* Able to read, understand, and speak English

Exclusion Criteria:

* Age \< 18 or \> 39 at initial cancer diagnosis
* Diagnosed with stage I/II solid malignancy, low-grade brain tumor, or hematologic malignancy
* Not receiving primary oncologic care at Mayo Clinic Arizona
* Unable to read, understand, and speak English
* Patients \> 12 months from initial diagnosis or advanced stage relapses, in survivorship or on hospice
* No internet or computer/smart phone access

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status	Contact
Scottsdale/Phoenix, Ariz. Mayo Clinic principal investigator Allison Rosenthal	Open for enrollment	Contact information: Oluwaseyitan Oloyede (507) 538-6811 Oloyede.Oluwaseyitan@mayo.edu
Rochester, Minn. Mayo Clinic principal investigator Allison Rosenthal	Open for enrollment	Contact information: Oluwaseyitan Oloyede (507) 538-6811 Oloyede.Oluwaseyitan@mayo.edu

Mayo Clinic Location

Status

Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Allison Rosenthal

Open for enrollment

Contact information:

Oluwaseyitan Oloyede

(507) 538-6811

Oloyede.Oluwaseyitan@mayo.edu

Rochester, Minn.

Mayo Clinic principal investigator

Allison Rosenthal

Open for enrollment

Contact information:

Oluwaseyitan Oloyede

(507) 538-6811

Oloyede.Oluwaseyitan@mayo.edu

More information

Publications

Publications are currently not available

Clinical Trials